JATT Acquisition Corp. (JATT) Shareholders Approve Zura Bio Deal
by Marlena Haddad on 2023-03-16 at 4:47pm

JATT Acquisition Corp. (NYSE: JATT) announced this afternoon that its shareholders have approved its combination with clinical-stage biotechnology company Zura Bio.

A total of 4,907,863 ordinary shares, or 95.5% of JATT’s issued and outstanding ordinary shares, were present at today’s special meeting. The business combination was overwhelmingly approved as holders of 4,903,764 ordinary shares, or 99.9% of the votes cast at the meeting, voted in favor of the deal.

The parties expect to close the deal on March 20 after all closing conditions are satisfied or waived. The combined company’s ordinary shares and warrants are anticipated to begin trading on the Nasdaq on March 21 under the new ticker symbols, “ZURA” and “ZURAW”, respectively.

The SPAC disclosed last week that following the close, it will issue 2,500,000 new shares to its FPA investors. FPA investors Athanor Master Fund and affiliates already agreed to expand their FPA purchases last month to 3,000,000 shares at $10 per share and provide a binding redemption backstop of $15 million covering any redemptions in excess of 90%.

JATT initially announced its $215 million business combination with Zura Bio in June 2022. London-based Zura Bio is a clinical-stage firm developing novel medicines for immune disorders with an initial focus on alopecia.


ADVISORS

  • Raymond James & Associates, Inc. and its affiliates (together, “Raymond James”) is acting as the lead PIPE placement agent
  • Raymond James & Associates, Inc. is financial advisor to JATT in the transaction.
  • McDermott Will & Emery LLP is acting as legal counsel to Zura Bio.
  • Ogier is acting as legal counsel to Zura Bio.
  • Loeb & Loeb LLP and Simmons & Simmons are acting as legal counsel to JATT
  • Maples and Calder (Cayman) LLP are acting as Cayman Islands legal counsel to JATT.
  • Paul Hastings LLP is acting as legal counsel to Raymond James.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-24 at 8:07am

At the SPAC of Dawn Although the market has largely recovered from a negative stretch last week, the roller coaster is tilted back downward for Trump Media (NASDAQ:DJT), which slid -8% yesterday to $32.57 – one of its lowest points since closing with Digital World last month. Other SPACs and de-SPACs are having a more...

by Nicholas Alan Clayton on 2024-04-23 at 4:05pm

Remember the metaverse? Many do not. Meta’s (NASDAQ:META) attempted transition to virtually living and working seemed to mark a trend that went up and down quickly, but one SPAC deal has both survived that roller coaster and may rise with a second. Back in December 2022, Newbury Street (NASDAQ:NBST) announced a $1.85 billion combination with...

by Nicholas Alan Clayton on 2024-04-23 at 7:50am

At the SPAC of Dawn Tucked into the bill that provides $95 billion in funding to American allies passed by the House this weekend is another measure that is likely to have far more impact on at least one pending deal in SPAC world. It would appear that the timing was fortuitous for TikTok rival...

by Nicholas Alan Clayton on 2024-04-22 at 3:01pm

With the passage this weekend of $95 billion in funding for Ukraine, Israel and Taiwan by the House of Representatives, some focus has gone back towards the defense sector, which has generally had a good year as a whole. But, SPACs have not been as active in defense, despite the fact that companies in the...

by Nicholas Alan Clayton on 2024-04-22 at 7:51am

At the SPAC of Dawn As April’s sleepy month for SPAC news continues, there is only one special meeting on the docket to consider a SPAC deal approval, that being today’s vote on Pegasus Digital Mobility‘s (NYSE:PGSS) combination with equipment manufacturer Schmid. Three more SPACs are facing extension votes this week, including Pyrophyte (NYSE:PHYT), whose...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved